Hidden Late-Onset SpA in PMR: Who Are These Patients?
Patients initially diagnosed with polymyalgia rheumatica (PMR) but later reclassified as having spondyloarthritis (SpA) showed bone marrow edema of the spine and sacroiliac joints on MRI. They also responded poorly to glucocorticoid therapy or were unable to taper off steroids and were more likely to benefit from treatment using TNF inhibitors or interleukin-17 (IL-17) inhibitors.
METHODOLOGY:
Researchers at a hospital in Leeds, England, screened patients with psoriatic arthritis or axial SpA to identify those who were initially diagnosed with PMR from 2002 to 2024.
They analyzed the data of 31 patients (median age, 62 years; 17 women) who fulfilled standard diagnostic criteria for PMR and were subsequently diagnosed with SpA.
Conventional radiography, MRI of the spine and sacroiliac joints, and FDG PET-CT were performed to confirm a diagnosis of SpA in patients with PMR and to exclude those with other conditions.
TAKEAWAY:
Among the 31 patients, 12 (38.7%) were diagnosed with SpA within 3 months of initial presentation, whereas the remaining 19 (61.3%) received their diagnosis after a median follow-up duration of 3 years due to persistent musculoskeletal symptoms and failure to taper glucocorticoids. The presence of psoriasis and a family history of SpA were associated with an early diagnosis of SpA.
On MRI, bone marrow edema — a hallmark of SpA — was evident in the sacroiliac joints of 17 patients, the spine of 15 patients, and both sites in 20 patients.
Symptoms of PMR completely resolved in 21 of 31 patients following initial glucocorticoid therapy, whereas 10 patients showed a clinically partial response to glucocorticoid therapy. Additionally, seven of the 21 initial responders experienced disease flares during follow-up (median duration, 5 years).
During follow-up, one third of the patients were started on biologics such as anti-TNF-alfa and anti-IL-17 agents, both of which are recommended first-line treatments for axial SpA; at the last visit, eight patients were receiving conventional disease-modifying antirheumatic drugs, and 11 were receiving biologics.
IN PRACTICE:
'In PMR cases with refractory symptoms or difficult GC [glucocorticoid] reduction, these findings raise the possibility that MRI may have a role in more accurate identification of a subset of PMR/SpA overlap, with potential treatment implications,' the authors wrote.
SOURCE:
The study was led by Kerem Abacar, MD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds. It was published online on July 22, 2025, in Arthritis & Rheumatology.
LIMITATIONS:
This study did not discuss any limitations.
DISCLOSURES:
No financial support was received for this study. Some authors declared receiving grants, contracts, consulting fees, payments or honoraria, and support for attending meetings or having other ties with various pharmaceutical companies.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Gizmodo
6 minutes ago
- Gizmodo
Newly Discovered Fossils Reveal Unknown Humanlike Relative
Researchers have uncovered fossils belonging to a previously unknown ancient human relative. And they may have lived in the same time and place as the earliest-known members of the genus Homo, from which modern humans evolved, according to a new study. A team of archeologists working at Ethiopia's Ledi-Geraru research project area unearthed a set of fossilized teeth that likely belonged to an unidentified species within the Australopithecus genus, known for having both human- and ape-like traits. The findings are published in Nature. Until now, scientists have discovered six Australopithecus species in sites in Africa, including the famous Lucy fossil. But not all of these species intersected with our earliest human ancestors in the genus Homo. The newly found teeth, from two individuals, date back 2.6 to 2.8 million years. While they share some characteristics with other Australopithecus species, comparisons with nearby fossils and other hominin specimens indicate they are distinct enough to be considered a new species. At the same site, the scientists also discovered three other teeth that likely belonged to members of the earliest species of Homo, dating to 2.59 million years ago. That species was first identified in 2013 through a jawbone at the same study site. These discoveries suggest that as many as four early human-like lineages—Homo, Paranthropus, Australopithecus garhi, and the newly identified species—may have coexisted in East Africa between 2.5 and 3.0 million years ago. 'This new research shows that the image many of us have in our minds of an ape to a Neanderthal to a modern human is not correct—evolution doesn't work like that,' Kaye Reed, a paleoecologist at Arizona State University, said in a statement. 'Here we have two hominin species that are together. And human evolution is not linear, it's a bushy tree, there are lifeforms that go extinct.' The researchers need more fossils from the species to officially give it a name. But for now, the researchers have dubbed the new genus Ledi-Geraru Australopithecus. How these early ancestors were able to coexist is still a mystery, but it's possible that they ate different things and weren't competing for the same resources. The scientists are currently examining the enamel of the newly discovered teeth to figure out what these species may have eaten. 'Whenever you have an exciting discovery, if you're a paleontologist, you always know that you need more information,' Reed said in a statement. 'You need more fossils. That's why it's an important field to train people in and for people to go out and find their own sites and find places that we haven't found fossils yet.'
Medscape
6 minutes ago
- Medscape
Cycling and Education for Hip OA: A Cost-Effective Solution?
TOPLINE: A cycling and education intervention significantly improved self-reported function in hip osteoarthritis (OA) compared with standard physiotherapy. The group-based intervention was also cost-effective, with a cost per quality-adjusted life year below the National Institute for Health and Care Excellence (NICE) threshold. METHODOLOGY: Researchers conducted a pragmatic randomized controlled trial comparing a group-based cycling and education intervention with usual physiotherapy care for hip OA (the CLEAT trial) in Bournemouth, UK. A total of 221 patients (mean age, 64.4 years; 57% women; 98% White) with hip OA, as defined by NICE criteria, who met the primary care criteria for exercise referral were randomly assigned to either cycling against hip pain intervention (CHAIN, 110 participants) or usual physiotherapy care (111 participants). Participants in the cycling group attended an 8-week program comprising education and static cycling sessions at a local leisure center, facilitated by a physiotherapist and a gym instructor, respectively. The physiotherapy group received usual one-to-one care, including exercise, education, and other physiotherapy techniques, at the local hospital or by telephone. The primary outcome was the between-group difference in the self-reported function of performing everyday activities, measured using the Hip Disability and Osteoarthritis Outcome Score (HOOS) activities of daily living subscale at 10 weeks post-treatment. The analysis included a parallel economic evaluation from the perspective of the UK National Health Service (NHS) and personal social services, assessing cost per quality-adjusted life year at 3 months after treatment. TAKEAWAY: Patients in the cycling group showed a significant improvement in the HOOS activities of daily living score at 10 weeks post-treatment compared with those in the physiotherapy group (adjusted mean difference, 6.9; P = .0023). The cycling group experienced improvements in secondary outcomes, with significant increases in scores for symptoms and stiffness (P = .0072), sports (P = .022), and quality of life (P = .042), but no improvement in pain score. No significant differences were observed in physiologic measures such as BMI, blood pressure, or resting heart rate between the cycling and physiotherapy groups. The CHAIN intervention was cost-effective, with a base case analysis cost per quality-adjusted life year of £4092, and showed a high probability of cost-effectiveness at NICE thresholds compared with physiotherapy. IN PRACTICE: "Taken together, these findings add to a growing body of evidence suggesting that, although exercise is beneficial, between-group differences in function and pain are often small when comparing active interventions," the authors of the study wrote. "Although the study did not identify a clinically meaningful between-group difference, CHAIN's cost-effectiveness within the NHS positions it as a viable alternative to usual physiotherapy care," they added. "From the patient's perspective, cycling combined with patient education offers a simple and accessible treatment approach," experts wrote in an accompanying comment. "From the perspective of decision makers, the group-based nature of CHAIN presents a highly cost-effective option for implementation in first-line treatment. Given that a single healthcare provider can deliver this intervention to many patients at a time, CHAIN provides scalability and resource efficiency, which are essential in publicly funded healthcare systems." SOURCE: The study was led by Thomas W. Wainwright, PhD, University Hospitals Dorset NHS Foundation Trust in Bournemouth, UK. It was published online on July 31, 2025, in The Lancet Rheumatology. LIMITATIONS: Most participants did not have radiographic confirmation of OA, affecting baseline severity assessment. The inability to mask participants and treatment providers introduces a risk of performance bias, potentially influencing self-reported outcomes. The exclusion of individuals unable to complete the exercise tolerance test limits applicability to those with lower fitness levels. DISCLOSURES: The study was supported by the Research for Patient Benefit Programme of the National Institute for Health and Care Research. One author disclosed receiving institutional research funding and personal fees, while another author reported receiving royalties and consulting fees from various sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
News24
8 minutes ago
- News24
CEO paints bleak picture of Eastern Cape hospital earmarked for NHI implementation
Authorities at the Cecilia Makiwane Hospital in Mdantsane near East London have painted a bleak future about the facility's sustenance due to a critical staff shortage. Sithandiwe Velaphi / News24 Be among those who shape the future with knowledge. Uncover exclusive stories that captivate your mind and heart with our FREE 14-day subscription trial. Dive into a world of inspiration, learning, and empowerment. You can only trial once.
